Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Vorasidenib |
| Trade Name | Voranigo |
| Synonyms | AG-881|AG881 |
| Drug Descriptions |
Voranigo (vorasidenib) inhibits both mutant IDH1 and IDH2, thereby inhibiting cell proliferation in tumors expressing mutant IDH (PMID: 27292784, PMID: 32071674). Voranigo (vorasidenib) is FDA-approved for use in adult and pediatric patients 12 years and older with IDH-mutant grade 2 astrocytoma or oligodendroglioma following surgery (FDA.gov) |
| DrugClasses | IDH Inhibitor (Pan) 3 |
| CAS Registry Number | 1644545-52-7 |
| NCIT ID | C152914 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Pembrolizumab + Vorasidenib | Pembrolizumab Vorasidenib | 0 | 1 |
| PEPIDH1M vaccine + Vorasidenib | PEPIDH1M vaccine Vorasidenib | 0 | 1 |
| Temozolomide + Vorasidenib | Temozolomide Vorasidenib | 0 | 1 |
| Vorasidenib | Vorasidenib | 41 | 6 |